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Abstract
Background: Adenosine deaminase (ADA) and osteopontin (OPN) may play opposing roles in the pathogenesis of
COPD. Deficiency of ADA results in enhanced adenosine signaling which up-regulates OPN expression. Although
statins suppress OPN in cancer cells, little is known about their effects on ADA and OPN in COPD patients.
Methods: We extended a previous randomized double-blind placebo crossover study to investigate the effects of
simvastatin (20 mg/day) on sputum ADA and OPN expression and explored the underlying signaling pathways
involved by conducting in vitro experiments with cigarette smoke extract (CSE)-treated monocyte-derived
macrophages (MDM) from COPD patients and healthy subjects.
Results: Simvastatin decreased sputum IL-13, OPN and CD73, while increasing ADA expression, irrespective of inhaled
corticosteroid treatment and smoking status in parallel to increased inosine levels. The degree of simvastatin-restored
ADA activity was significantly correlated with the magnitude of changes in pre-bronchodilator FEV1. Mechanistic
exploration showed that CSE enhanced the expression of IL-13, which induced an increase in OPN and inhibited ADA
mRNA accumulation in MDM from COPD patients but not healthy subjects through a STAT6-dependent mechanism.
Simvastatin treatment inhibited IL-13 transcription in a dose-dependent manner, and therefore diminished the IL-13-
induced increase in OPN and restored IL-13-suppressed ADA. There was no effect of simvastatin on adenosine
receptors in CSE-stimulated MDM, indicating that its effects were on the adenosine pathway.
Conclusion: Simvastatin reversed IL-13-suppressed ADA activity that leads to the down-regulation of adenosine
signaling and therefore inhibits OPN expression through the direct inhibition of IL-13-activated STAT6 pathway.
Inhibition of IL-13 may reverse the imbalance between ADA and OPN in COPD and therefore may prevent COPD
progression.
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Background
Chronic obstructive pulmonary disease (COPD) is driven
by chronic inflammation and tissue remodeling process
in response to noxious particles or gases [1, 2]. Cur-
rently, there are no effective therapies that alter disease
progression and improve survival [2] due to the com-
plexity of signaling pathways that maintain chronic in-
flammation and tissue destruction [3].
Adenosine plays a key role in airway inflammation and
remodeling in COPD [4]. Extracellular adenosine was
produced upon cell damage to balance tissue repair
against excessive airway remodeling in COPD [5–10].
Conversely, in prolonged or repeated tissue injury,
chronic adenosine elevation can activate signaling path-
ways that promote tissue injury [5, 9]. Extracellular ad-
enosine production is regulated by ecto-5'-nucleotidase
(CD73); the rate-limiting step that converts AMP to ad-
enosine [11]. CD73 expression and activity is markedly
increased in patients with severe COPD, suggesting the
high production of adenosine [3]. Adenosine can either
interact with adenosine receptors or be transported into
cytosol via facilitated nucleoside transporters [12]. Ad-
enosine can be deaminated to inosine by adenosine
deaminase (ADA) [13]. Adenosine is upregulated in IL-
13-transgenic mice through the suppression of ADA ac-
tivity and mRNA accumulation [14]. The synergistic
effect of adenosine and IL-13 may contribute to the se-
verity of airway inflammation and fibrosis in COPD [14].
Suppression of ADA activity together with CD73 up-
regulation promotes adenosine production in the COPD
lungs [3]. The association between defective ADA activ-
ity and COPD was demonstrated in ADA-deficient mice
[15]. The pathological features of COPD was prevented
and reversed by lowering adenosine levels with exogen-
ous PEG-ADA [14–17].
Osteopontin (OPN) can function both as a matrix pro-
tein and a pleiotropic cytokine. OPN expression is regu-
lated by IL-13 that can be induced by cigarette smoke
extract [18, 19]. OPN accumulation in smokers corre-
lates with the degree of airflow limitation [20]. Sputum
OPN is significantly higher in COPD patients than in
healthy smokers in agreement with the extent of emphy-
sema [21]. In COPD lungs, OPN is primarily localized in
alveolar macrophages and to a lesser extent in epithelial
cells, T cells and fibroblasts [22]. Both adenosine and
OPN are involved in COPD pathogenesis. ADA defi-
ciency causes OPN-dependent neutrophilia and alveolar
air-space enlargement [22]. Increasing adenosine signal-
ing in severe COPD is directly associated with increased
OPN transcripts [3, 22]. Therefore, the simultaneous in-
hibition of OPN as well as adenosine might be an add-
itional strategy for prevention of COPD progression in
particular deterioration of lung function caused by air-
way fibrosis.
Statins inhibit the synthesis of the cholesterol isopren-
oid intermediates farnesylpyrophosphate (FPP) and
geranylgeranyl pyro-phosphate (GGPP) [23]. Statins sup-
pressed OPN mRNA and protein expression in an ovar-
ian cancer cell line due to several diverse homologous
cis-acting consensus sequences in human OPN pro-
moters [24, 25]. In addition, this suppression may result
from statin-depleted isoprenoids [26] that affects the ex-
pression of OPN [27]. However, the effect of simvastatin
in the context of IL-13-regulated adenosine and OPN in
COPD patients is not known.
We have demonstrated that simvastatin reversed IL-
13-suppressed ADA activity in COPD patients that leads
to the down-regulation of adenosine signaling and there-
fore inhibits OPN expression through the direct inhib-
ition of IL-13-activated STAT6 pathway. Simvastatin-
restored ADA activity positively correlated with the
magnitude of changes in pre-bronchodilator FEV1. In-
hibition of IL-13 may reverse the imbalance between
ADA and OPN in COPD and therefore may prevent
COPD progression.
Methods
Patients
Outpatients aged 45–80 years with a diagnosis of COPD,
defined in accordance with the European Respiratory
Society (ERS) consensus statement [28], who were
current or ex-smokers with ≥10 pack-year history
were recruited. They had a pre-bronchodilator forced
expiratory volume in 1 s (FEV1) of < 80 % predicted
normal values and a post-bronchodilator FEV1/forced
vital capacity (FVC) < 70 %. Exclusion criteria have
been described previously [29]. Patients who suffered
acute exacerbations before study period were ex-
cluded. All subjects and donors gave written informed
consent to a study protocol approved by the ethical
committee of Faculty of Medicine Siriraj Hospital
(Si323/2013).
Study design
The study design has been described in detail previously
[29]. The study was a 4-week randomized double-blind
crossover study with a 4-week washout period compar-
ing the effect of oral simvastatin treatment (20 mg once
daily) with that of a matched placebo on sputum cyto-
kine biomarkers and airway inflammation in COPD.
During the 2-week run-in period and throughout the
study, subjects continued their usual COPD medication
and withdrew statin therapy for 4 weeks prior to the
study entry if they were taking regular treatment. The
study was listed on all appropriate clinical trial registries
(ClinicalTrials.gov identifier: NCT01944176). Methods
pertaining specifically to the current analysis will be de-
scribed here.
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Measurement
Demographic measurements were recorded on the first
clinical visit (visit 1 screening). Induced sputum and
blood samples were collected before and after treatment
periods for analysis of sputum cytokines. Spirometry was
measured at all study visits. The description of sputum
induction and processing of sputum samples, and other
methodology related to this study can be found in
Additional file 1.
Statistical analysis
Data are presented as means ± SD or median (interquartile
range; IQR) as appropriate. Response to simvastatin on
sputum mediator levels versus placebo was assessed by
general linear model for the standard 2 × 2 crossover de-
sign. When variables were unsuitable for this, the within-
patient treatment differences were calculated and then an-
alyzed by paired t-test for parametric and Wilcoxon
Signed Rank test for non-parametric data. The effects of
ICS treatment and smoking status on the response to
simvastatin was analyzed by unpaired t-test. The rs
correlation coefficient was determined for the correl-
ation of ADA and OPN with baseline pre-BD FEV1
and absolute changes in ADA and pre-bronchodilator
(BD) FEV1 using Spearman’s rank correlation test and
Pearson correlation coefficients, respectively. Statis-
tical analysis for multiple comparisons was performed
using one-way ANOVA and Welch test with Games-
Howell correction for equal variances not assumed or
Bonferroni corrections for equal variances assumed.
Dunnett t tests was used for dose–response analysis.
All statistical tests were two-sided, and significance
was accepted at the level of 95 % and P < 0.05 using
PASW statistics 18 (SPSS, IBM, Somers, NY).
Results
Flow of subjects through the study, demographic data,
sputum cytology in response to simvastatin were previ-
ously described (Table 1) [29]. Pre-BD FEV1 values were
positively correlated with baseline ADA but negatively
correlated with OPN (rs = 0.76; p < 0.001, rs = −0.75;
p < 0.001, respectively) (Fig. 1a, 1b).
Simvastatin enhanced ADA transcription and translation
Simvastatin increased ADA transcripts in sputum cells
(p = 0.0002) and ADA levels in sputum supernatants
(p < 0.001) (Table 2). The magnitude of the increase in
ADA transcripts was 2.8 folds (95 % CI 1.3–4.2, p = 0.001)
and ADA levels were 23.3 U/L (95 % CI 15.0–31.6,
p < 0.001) (Table 3). Neither ADA transcription (p = 0.84)
nor translation (p = 0.47) was altered in placebo-treated
COPD. This effect was independent from the treatment
sequence (simvastatin and placebo, p = 0.7 for ADA
mRNA, p = 0.19 for ADA). ICS did not alter the effect of
simvastatin on ADA (p = 0.73). Smoking status did not in-
fluence ADA response to simvastatin (p = 0.31). The ADA
enhancement was associated with pre-BD FEV1 improve-
ment (r =0.59; p = 0.0049) (Fig. 1c).
Simvastatin suppressed CD73 transcription and protein
expression
Simvastatin decreased CD73 transcript and the number
of CD73-expressing sputum cells (−0.91 folds (95 % CI
−0.37 to −1.5), p = 0.01; −8.3 % (95 % CI −13.8 to −2.7),
p = 0.006, respectively) (Table 3). This effect was inde-
pendent from the treatment sequence (simvastatin and
placebo, p = 0.99 for CD73 mRNA and p = 0.92 for
CD73).
Simvastatin treatment increased sputum inosine levels
Simvastatin significantly increased whereas placebo de-
creased sputum inosine (p < 0.001 and p = 0.0034, re-
spectively) (Table 2). In addition, the magnitude of the
increase in inosine levels was 0.37 nmol (95 % CI 0.29–
0.43, p < 0.001) (Table 3).
Simvastatin inhibited OPN transcription and translation
Simvastatin markedly decreased OPN transcripts in
sputum cells (p < 0.001) and OPN levels in sputum su-
pernatants (p < 0.001), whereas placebo treatment caused
Table 1 Patient characteristics
Clinical parameters All patients (n = 21)
Age (yr) 68.4 ± 7.8
Sex: M: F 19:2
Smoking (pack-yr) 36.7 ± 28.9
Ex-smoker: current smoker (n) 16:5
Pre-BD FEV1/FVC (%) 53.9 ± 11.5
Post-BD FEV1/FVC (%) 55.7 ± 11.6
Post-BD FEV1 (L) 1.55 ± 0.6
Post-BD FVC (L) 2.7 ± 0.7
Δ FEV1 (mL) 115.2 ± 108.0
BD reversibility (%) 9.5 ± 8.9
DLCO (ml/mmHg/min) 57.4 ± 21.2
DLCO/VA (ml/mmHg/min/l) 62.4 ± 14.2
ICS/LABA use (n) 8
LAMA use (n) 1
Triple therapy (n) 7
Oral bronchodilator (n) 8
Previous statin therapy (n) 8
Data are presented as mean ± SD unless otherwise indicated
BD bronchodilator, Δ change in, DLCO diffuse lung capacity to carbon
monoxide, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity,
ICS inhaled corticosteroid, LABA long-acting β2 agonist, LAMA long-acting
muscarinic antagonist, VA alveolar volume
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increased OPN transcription (p = 0.026) but not OPN
levels (p = 0.25) (Table 2). The magnitude of the reduc-
tion in OPN transcripts was 2.4 folds (95 % CI −4.1 to
−0.6, p = 0.012) and OPN levels were 0.85 ng/ml
(95 % –1.2 to −0.5), p < 0.001) (Table 3). This sup-
pression was independent from the treatment se-
quence (simvastatin and placebo, p = 0.69 for OPN mRNA
and p = 0.92 for OPN). ICS did not alter the effect of
simvastatin on OPN (p = 0.84). Smoking status did not in-
fluence OPN response to simvastatin (p = 0.73).
Because IL-13 is induced by adenosine and induces
OPN expression [18, 30, 31], we investigated whether
simvastatin suppresses IL-13 production in the air-
ways of COPD patients. We found that simvastatin
markedly decreased sputum IL-13 levels (−15.0 pg/ml
(95 % CI −20.4 to −9.6), p < 0.001) compared with
Fig. 1 The data shows a positive correlation between baseline pre-BD FEV1 and ADA (a) and negative correlation with OPN levels (b) and the
association between the magnitude of changes in ADA levels and the degree of pre-BD FEV1 improvement (c)
Table 2 Baseline induced sputum cytology and inflammatory marker levels and before-after each treatment
Variable Baseline Placebo P value Simvastatin P value
Before After Before After
Sputum mediators
ADA mRNA
(fold change) (n = 13)
1.03 ± 0.06 1.04
[1.0-1.05]
1.01
[0.7-1.4]
0.84 1.0
[1.0-1.0]
2.7
[2.3-2.9]
0.0002
ADA (U/L) 29.5 ± 8.9 29.8 ± 10.4 28.3 ± 9.4 0.47 28.7 ± 10.7 50.6 ± 23.7 <0.001
OPN mRNA
(fold change) (n = 13)
1.0 ± 0.0 1.0
[1.0-1.0]
2.2
[0.8-4.2]
0.026 1.0
[1.0-1.0]
0.4
[0.2-0.6]
<0.001
OPN (ng/mL) 1.5 ± 0.6 1.6 ± 0.7 1.8 ± 0.9 0.25 1.7 ± 0.6 0.9 ± 0.5 <0.001
CD73 mRNA
(fold change) (n = 13)
1.0 ± 0.02 1.0
[1.0-1.01]
1.05
[0.97-2.3]
0.065 1.0
[1.0-1.01]
0.8
[0.2-1.02]
0.057
Total CD73 (%) 12.4 ± 9.1 9.6
[3.5-12.6]
4.8
[1.5-13.6]
0.76 12.3
[5.0-25.1]
5.7
[2.5-9.2]
0.0071
Inosine (nmol) 0.57 ± 0.1 0.59 ± 0.1 0.52 ± 0.1 0.0034 0.5 ± 0.2 0.8 ± 0.1 <0.001
IL-13 (pg/ml) 26.3 ± 7.9 25.4 ± 8.9 23.4 ± 11.7 0.36 27.8 ± 6.6 10.9 ± 8.2 <0.001
Data was presented as mean ± SD or median [IQR] as appropriate and indicated
ADA adenosine deaminase, IL interleukin, OPN osteopontin
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placebo (Table 3). However, we could not exclude the
possibility that the effect of simvastatin on IL-13 was
due to either the direct suppression or the conse-
quence of decreased adenosine as a result of ADA
augmentation or both as adenosine could stimulate
IL-13 [30]. This prompted mechanistic studies in
MDM from COPD patients.
Mechanistic investigations in CSE-treated MDM
To determine whether IL-13 regulated OPN and ADA
expression in CSE-stimulated MDM from COPD pa-
tients, we inhibited IL-13 using siRNA. CSE enhanced
OPN and inhibited ADA transcription through IL-13 in-
duction (mean fold change ± SD: 6.3 ± 1.9 vs 1.0 ± 0.02,
p < 0.001; 0.46 ± 0.2 vs 1.39 ± 0.4, p < 0.001; 12.8 ± 2.1 vs
1.02 ± 0.2, p < 0.001, respectively) (Fig. 2a-c) whereas IL-
13 mRNA expression was suppressed in CSE-treated
MDM from normal subjects, resulting in downregula-
tion of OPN and upregulation of ADA transcription
(0.31 ± 0.1 vs 1.02 ± 0.2, p < 0.001; 0.44 ± 0.1 vs 1.0 ± 0.04,
p < 0.001; 1.7 ± 0.3 vs 1.0 ± 0.03, p < 0.001, respectively)
(Fig. 3g-i). IL-13 knockdown decreased OPN and in-
creased ADA in both transcript and protein levels
(mean fold change ± SD: 0.77 ± 0.4 vs 5.4 ± 1.3, p < 0.001;
9.0 ± 1.9 ng/ml vs 21.6 ± 1.6 ng/ml, p < 0.001 for
OPN, 5.0 ± 0.9 vs 0.63 ± 0.5, p < 0.001; 14.8 ± 4.0 U/L vs
4.8 ± 1.9 U/L, p < 0.001 for ADA). These alterations
could be completely reversed by exogenous IL-13 in
both MDM from COPD patients (Fig. 2b-e) and
healthy subjects (Fig. 3h and 3i), indicating the OPN
positive regulation and ADA negative regulation by
IL-13. The IL-13 effect was mediated through STAT6
as STAT6-knockdown antagonized CSE-induced OPN
transcription induction and ADA transcription inhib-
ition (mean fold change ± SD: 0.83 ± 0.38 vs 3.75 ± 0.37,
p < 0.001; 3.4 ± 0.38 vs 0.75 ± 0.4, p < 0.001, respectively).
Stimulation of STAT6 signaling with IL-13 induced OPN
and inhibited ADA transcripts when compared with
STAT6 knockdown (3.5 ± 0.52, p < 0.001 for OPN;
1.01 ± 0.58, p < 0.001 for ADA) (Figs. 2f and 3g).
We investigated whether simvastatin affected IL-13-
mediated alterations to OPN and ADA expression in
CSE-treated MDM from COPD patients. Simvastatin
inhibited IL-13 mRNA expression in a dose-dependent
manner (Fig. 3a). Simvastatin at therapeutic range
(2 ng/mL) [32] was used in subsequent experiments.
Simvastatin markedly decreased OPN transcripts and pro-
tein levels (mean fold changes ± SD, 3.0 ± 1.1 vs 6.3 ± 1.9,
p < 0.001; 8.3 ± 1.7 ng/ml vs 22.1 ± 2.8 ng/ml, p < 0.001, re-
spectively) (Fig. 3b, 3c) in MDM from COPD patients
whereas simvastatin had no any effect on IL-13, OPN,
and ADA in CSE-treated MDM from healthy subjects
(0.36 ± 0.1 vs 0.31 ± 0.1, p = 0.5; 0.5 ± 0.1 vs 0.44 ± 0.1,
p = 0.67; 1.5 ± 0.2 vs 1.7 ± 0.3, p = 0.62) (3g-i). This
suppression in MDM from COPD patients was reversed
when IL-13 was added (for OPN transcripts 5.0 ± 1.6 vs
3.0 ± 1.1, p < 0.001; for OPN levels 20.7 ± 1.6 ng/ml vs
8.3 ± 1.7 ng/ml, p < 0.001). In contrast, simvastatin mark-
edly enhanced ADA transcripts and protein levels (1.8 ±
0.3 vs 0.46 ± 0.2, p < 0.001; 14.3 ± 4.4 U/L vs 3.1 ± 1.9 U/L,
p < 0.001) that could be reversed by exogenous IL-13
(0.42 ± 0.2 vs 1.8 ± 0.3, p < 0.001; 3.3 ± 1.8 U/L vs 14.3 ±
4.4 U/L, p < 0.001) (Fig. 3d and 3e). Therefore, simvastatin
inhibited IL-13 and consequently reduced OPN and in-
creased ADA in CSE-treated MDM.
We tested whether the simvastatin induced OPN sup-
pression was mediated through inhibition of STAT6-
dependent IL-13 signaling. CSE markedly increased,
whereas simvastatin dramatically decreased STAT6
phosphorylation in MDM (45.7 ± 8.8 % vs 10.3 ± 3.0 %,
p < 0.001; 16.4 ± 6.5 % vs 45.7 ± 8.8 %, p < 0.001, respect-
ively) (Fig. 3f ). The inhibition of STAT6 phosphorylation
by simvastatin could be reversed by IL-13 (54.0 ± 10.7 %,
p < 0.001). Simvastatin did not alter the expression of
A1R, A2AR, A2BR or A3R, but CSE increased A3R ex-
pression (Fig. 4).
Table 3 The effect of simvastatin on sputum cell count and cytokines
Sputum cells Placebo
(n = 21)
Simvastatin
(n = 21)
P value Treatment difference,
simvastatin minus placebo
(95 % CI)
Effects by order
P value
Δ sputum ADA mRNA (fold change) (n = 13) 0.3 ± 1.4 2.8 ± 3.1 0.001 2.8 (1.3 to 4.2) 0.7
Δ sputum ADA (U/L) −1.5 ± 9.4 22.0 ± 18.4 <0.001 23.3 (15.0 to 31.6) 0.19
Δ sputum osteopontin mRNA (fold change) (n = 13) 1.6 ± 2.5 −0.6 ± 0.3 0.012 −2.4 (−4.1 to −0.6) 0.69
Δ sputum osteopontin (ng/mL) 0.15 ± 0.6 −0.71 ± 0.6 <0.001 −0.85 (− 1.2 to −0.5) 0.92
Δ sputum inosine (nmol) −0.1 ± 0.1 0.3 ± 0.2 <0.001 0.37 (0.29 to 0.43) 0.054
Δ sputum CD73 mRNA (fold change) (n = 13) 0.7 ± 1.3 −0.2 ± 0.6 0.01 −0.91 (−0.37 to −1.5) 0.99
Δ sputum CD73 (%) 0.58 ± 8.7 −7.5 ± 13.6 0.006 −8.3 (−13.8 to −2.7) 0.92
Δ sputum IL-13 (pg/mL) −2.0 ± 9.9 −16.9 ± 8.3 <0.001 −15.0 (−20.4 to −9.6) 0.69
Data are presented as mean ± SD
ADA adenosine deaminase, IL interleukin, OPN osteopontin
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Discussion
We have demonstrated for the first time that simva-
statin enhances ADA expression while inhibiting
osteopontin via inhibition of STAT6-dependent IL-13
signaling. In addition to ADA enhancement, simva-
statin suppressed CD73 expression, both of which re-
sulted in increasing sputum inosine. Our study
confirmed the diametrically opposed role of OPN and
ADA in patients with COPD. Osteopontin were in-
versely correlated, whereas ADA levels were directly
correlated with pre-BD FEV1. Simvastatin-restored
ADA activity was associated with improving pre-BD
FEV1. Our mechanistic exploration in vitro suggested
that CSE enhanced IL-13 that induced OPN but sup-
pressed ADA in COPD-derived MDM via the STAT6-
dependent pathway whereas in healthy-derived MDM,
CSE suppressed IL-13, resulting in the reverse effect
to OPN and ADA transcription. Simvastatin inhibited
CSE-enhanced IL-13 in a dose-dependent manner and
subsequently decreased STAT6 phosphorylation, leading
Fig. 2 a The effect of CSE on IL-13 transcription. The effect of knockdown of IL-13 transcripts on OPN (b) and ADA mRNA expression (c), OPN (d)
and ADA (e). The effect of knockdown of STAT6 on OPN (f) and ADA mRNA expression (g). Results are expressed as the means (±SD)
values of six independent experiments from 6 COPD patients. **, p < 0.001 vs control
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to the reciprocal induction of ADA and inhibition of
OPN. In addition, simvastatin did not affect adenosine re-
ceptor expression and had no inhibitory effects on IL-13,
OPN, and ADA in CSE-treated MDM from healthy
subjects.
Statins have strong immune-modulating effects in
both the systemic and pulmonary inflammation, which
could have substantial benefits in patients with COPD
[33]. Anti-inflammatory effects of statins are mediated
through inhibition of key inflammatory and remodeling
pathways [33]. This is supported by the recent study
showing that statins significantly reduced airway and
pulmonary neutrophils in stable COPD [34]. Our previ-
ous study also demonstrated that statin therapy could
suppress IL-17 and restore IL-10 in COPD although this
was associated with reduction in alveolar macrophages
but not neutrophils as previously explained [29]. There-
fore, statins may attenuate progressive decline in lung
function although there have been very few studies in-
vestigating signaling molecules simultaneously involved
in both inflammatory and fibrogenic activities including
OPN and IL-13.
Fig. 3 a Inhibitory effects of simvastatin on IL-13 mRNA expression in CSE-treated MDM from COPD patients in a dose-dependent manner. The
inhibitory effects of simvastatin (2 ng/ml) on OPN mRNA expression (b) and protein concentration (c), and STAT6 phosphorylation (f). The enhancing
effects of simvastatin (2 ng/ml) on ADA mRNA expression (d) and protein concentration (e). MDM from healthy subjects were used to demonstrate
the effect of CSE and simvastatin on IL-13, OPN, and ADA transcription (g, h, i, respectively). This also illustrates the reversal of the above effects of
simvastatin by the addition of exogenous human recombinant IL-13. Results are expressed as the means (±SD) values of six independent experiments
from 6 COPD patients and 4 healthy subjects. *, p < 0.05 and **, p < 0.001 vs control
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IL-13 polymorphism is associated with an increased
risk of COPD [35–37]. Alveolar or extrapulmonary mac-
rophages produce IL-13 in response to rhinovirus or
parasitic infection in mice [38, 39]. CSE may induce IL-
13 producing murine macrophage M2 polarization in
mice, either through its direct effect on JAK/STAT3 or
indirectly through mast cell-associated mechanisms
[40, 41]. In addition, a previous study showed that
RSV infection enhanced cigarette smoke-induced IL-13
gene expression, but not IL-13 release, in mice although
the cellular source of IL-13 was not identified [42]. CSE
induces IL-13 secretion by macrophages in mice. How-
ever, there are very few data addressing the ability of CSE
to induce an IL-13 response in human macrophages from
patients with COPD. We have demonstrated that CSE
markedly induced IL-13 response with STAT6 activation
in MDM from COPD patients. However, this was not the
case for the effect of CSE on IL-13 in healthy-derived
MDM that revealed in reverse, possibly preventing healthy
MDM from the establishment of IL-13/OPN axis.
Therefore, CSE-stimulated COPD-derived MDM could
be used in our study to investigate the effects of sim-
vastatin on CSE-induced IL-13-mediated OPN and
ADA expression.
OPN induces airway neutrophilic inflammation and
airway remodeling [22] and its expression is increased in
patients with COPD [3, 21]. Simvastatin may suppress
pro-inflammatory and induce anti-inflammatory cytokines
Fig. 4 None of the effects of simvastatin on A1R (a), A2AR (b), A2BR (c) and A3R (d). Results are expressed as the means (±SD) values of six
independent experiments from 6 COPD patients
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in COPD [29]. Furthermore, simvastatin inhibits IL-
13 inducible OPN gene in airway epithelial cells.
However, whether IL-13 regulates OPN expression
and whether simvastatin affected this in patients with
COPD is unknown. Therefore, the mechanistic un-
derstanding of how OPN accumulation is induced by
IL-13 and how simvastatin mediates its inhibitory ef-
fects on IL-13-induced OPN accumulation in COPD
patients may provide a new therapeutic target in fu-
ture. The present study is the first to investigate
whether CSE induces OPN transcription in an IL-13-
dependent manner and showed that silencing of IL-13
or STAT6 with siRNA resulted in the down-
regulation of CSE-enhanced induction of OPN and
the up-regulation of CSE-suppressed expression of
ADA. Furthermore, our findings confirmed and ex-
tended the previous data that in addition to inhibition
of CSE–induced increase in OPN expression [18, 27],
simvastatin also inhibited CSE-induced increase in IL-
13 production by MDM from patients with COPD in
a dose-dependent manner. In addition, the effect of
simvastatin on CSE-induced OPN expression could be
overcome by the addition of exogenous IL-13, con-
firming that inhibition of CSE-induced OPN by sim-
vastatin was mediated through IL-13 suppression.
Simvastatin reduces IL-13 levels with varying doses in
a mouse asthma and bleomycin-induced pulmonary
fibrosis model [43, 44]. However, our result is in
contradiction to previous studies in Th2-biased ani-
mal models in that simvastatin induced Ym1 in den-
dritic cells which resulted in the augmentation of IL-
13 release from Th2 cells [45]. This leads us to
speculate that there are varying effects of simvastatin
on IL-13 which are dependent upon specific cell types
and types of inflammation.
Several studies have shown that IL-13 is strongly in-
duced by adenosine in ADA knockout mice during an
inflammatory and remodeling response [14, 30, 31].
During this response, IL-13 causes a progressive ac-
cumulation of adenosine and inhibits ADA activity
and mRNA accumulation [14]. Our study demon-
strates the inhibitory effect of IL-13 on ADA in pa-
tients with COPD, and that simvastatin treatment
reverses IL-13-suppressed ADA in CSE-treated MDM
from COPD patients. Restoration of ADA as well as
inhibition of CD73 in the airways of COPD patients
by simvastatin could be the mutually beneficial con-
version of adenosine to inosine as exemplified by an
increase in sputum inosine levels. However, we could
not exclude the possibility that the reversal of ADA
suppression may diminish the IL-13-induced increase
in adenosine [14] and the possibility that this may be
enhanced by simvastatin-inhibited IL-13 in our COPD
patients.
IL-13 and adenosine stimulate each another in an
amplification pathway that may contribute to progres-
sion and/or chronicity of IL-13, which at least in part is
augmented by increased adenosine receptor expession
[14]. A1R, A2BR and A3R are elevated in the lungs of IPF
models. Previous data suggested that there was elevated
expression of A2BR in macrophages in COPD lung speci-
mens [3]. Persistent activation of A2BR signaling main-
tains inflammatory mediators, such as IL-6, IL-8, IL-13
and OPN [3], [46–48]. In contrast, another study
demonstrated elevation of A2AR and A3R but down-
regulation of A2BR transcripts [49]. The discrepancy be-
tween both studies may be related to differences in dis-
ease severity and smoking status. The present study has
demonstrated that simvastatin failed to suppress adeno-
sine receptors. This results indicates that the inhibitory
effects of simvastatin on IL-13 and OPN response is me-
diated through down-regulation of adenosine signaling
resulting from modulation of adenosine rather than its
receptors.
Our results were in the agreement with other previous
studies showing the beneficial effects of statins [50–52]
but differed from the results of the recent study
(STATCOPE) demonstrating no benefit [53]. A plaus-
ible explanation for the discrepancy between STATCOPE
and other previous studies including our study is the
inclusion of a large percentage of COPD patients with
coexisting overt cardiovascular disease who are ‘statin
users’ and ‘non-users’, but would benefit from statin
therapy. These comorbid phenotypes of COPD are
likely to express a poor prognosis due to one or a
combination of undertreated pulmonary inflammation,
unrecognized systemic inflammation or subclinical cardio-
vascular disease. These comorbid conditions are strongly
associated with an increased risk of hospitalization with
acute exacerbations and greater mortality [54–56].
Therefore, there is possibility that many patients with
COPD who have not been prescribed with statins in
other previous studies do badly from undertreatment,
a hypothesis mentioned by STATCOPE investigators
to explain this discordance [53]. Another explanation
for the STATCOPE findings is that COPD patients
with coexisting clinical and subclinical cardiovascular
disease underlying acute exacerbations has been all
but excluded [57, 58].
The present study has demonstrated the involvement
of IL-13 in CSE-induced OPN and simultaneously sup-
pressed ADA in MDM and the consistent imbalance be-
tween IL-13-regulated OPN and ADA in patients with
COPD. The balance toward IL-13-induced OPN can be
reversed by simvastatin treatment. However, whether the
reversal would provide the long-term benefit in lung
function decline for patients with COPD required fur-
ther study.
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Conclusions
This study provides the better understanding of the mo-
lecular mechanisms underlying the effects of simvastatin
on ADA/OPN balance in COPD patients. Simvastatin
treatment induces ADA and inhibits OPN expression in
the airways and monocyte-derived macrophages from
COPD patients. This effect is mediated through the dir-
ect inhbition of IL-13 activated STAT6 pathway which
drives the imbalance between ADA and OPN towards
the latter.
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